Recent Quotes (30 days)

You have no recent quotes
chg | %

Revive Therapeutics Ltd  

(Public, CVE:RVV)   Watch this stock  
Find more results for RVV
+0.005 (2.70%)
Oct 18 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.19 - 0.19
52 week 0.09 - 0.44
Open 0.19
Vol / Avg. 51,631.00/199,859.00
Mkt cap 10.24M
P/E     -
Div/yield     -
EPS -0.04
Shares 53.89M
Beta 0.70
Inst. own     -
Oct 18, 2017
Q4 2017 Revive Therapeutics Ltd Earnings Release (Estimated)

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -88.14% -135.09%
Return on average equity -105.71% -186.85%
CDP Score - -


5 Director Crt Suite 105
+1-905-6055535 (Phone)
+1-905-2483355 (Fax)

Website links


Revive Therapeutics Ltd (Revive) is engaged in commercializing treatments for rare diseases, such as Cystinuria, Wilson's disease and Rett syndrome. The Company has completed a Phase II-A study for acute gout flares in the United States. The Company's business model focuses on finding new uses of old drugs with the objective of finding a partner or partners to bring the new use drug to the marketplace. The Company is focused on the development of Bucillamine for the treatment of cystinuria (REV-004). The Company's product pipeline includes Bucillamine for the treatment of acute gout flares (REV-002), Tianeptine for treatment of Rett Syndrome (REV-003), and Bucillamine for treatment of Wilson's disease (REV-005). The Company is focused on the development and commercialization of drugs for underserved medical needs. The Company is also evaluating additional drug repurposing candidates and formulations.

Officers and directors

Craig Leon Chairman of the Board, Chief Executive Officer
Fabio Chianelli President, Director
Carmelo Marrelli Chief Financial Officer, Secretary
Robbie Grossman Director
Age: 40
Scott Johnson Director
Age: 36
Anton Konovalov Director
Age: 26
Reiza Rayman M.D. Director
Age: 53
Carlo Sansalone Director
Age: 35